Primary focal segmental glomerulosclerosis (FSGS) frequently recurs after kidney transplantation and is associated with poor graft survival. To date, few studies have investigated predictive factors for treatment responses in recurrent FSGS.
We retrospectively analyzed 16 patients who were < 16 years at the age of onset and had post-transplant recurrence of FSGS from 1993 to 2018. Patients who achieved complete remission or partial remission after initiating therapy for recurrent FSGS were defined as responders. We compared several clinical characteristics between responders and non-responders. Time to remission was also analyzed.
Ten patients were responders, and six patients were non-responders. Univariate analysis showed that responders had a significantly lower amount of maximum proteinuria at the time of recurrence (P = 0.015) and more highly selective proteinuria (P = 0.013) than non-responders. The time to remission from initiation of therapy was 2 months (interquartile range 0.2–4.4). In all responders, except for one patient, remission was achieved within 6 months.
Therapeutic responses may be predicted by examining the amount and selectivity of proteinuria at the time of recurrence. Further studies with larger numbers of patients are clearly required to validate these findings.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Canaud G, Delville M, Legendre C (2016) Recurrence of focal and segmental glomerulosclerosis after transplantation. Transplantation 100:284–287. https://doi.org/10.1097/tp.0000000000000902
Francis A, Trnka P, McTaggart SJ (2016) Long-term outcome of kidney transplantation in recipients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 11:2041–2046. https://doi.org/10.2215/cjn.03060316
Cosio FG, Cattran DC (2017) Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation. Kidney Int 91:304–314. https://doi.org/10.1016/j.kint.2016.08.030
Candelier JJ, Lorenzo HK (2020) Idiopathic nephrotic syndrome and serum permeability factors: a molecular jigsaw puzzle. Cell Tissue Res 379:231–243. https://doi.org/10.1007/s00441-019-03147-y
Burke GW 3rd, Fornoni A (2019) The elusive podocyte crossmatch for recurrent focal segmental glomerulosclerosis. Kidney Int 95:498–500. https://doi.org/10.1016/j.kint.2018.11.032
Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ (2019) Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the writing committee of the American Society for Apheresis: the eighth special issue. J Clin Apher 34:171–354. https://doi.org/10.1002/jca.21705
Garrouste C, Canaud G, Büchler M, Rivalan J, Colosio C, Martinez F, Aniort J, Dudreuilh C, Pereira B, Caillard S, Philipponnet C, Anglicheau D, Heng AE (2017) Rituximab for recurrence of primary focal segmental glomerulosclerosis after kidney transplantation: clinical outcomes. Transplantation 101:649–656. https://doi.org/10.1097/tp.0000000000001160
Shishido S, Satou H, Muramatsu M, Hamasaki Y, Ishikura K, Hataya H, Honda M, Asanuma H, Aikawa A (2013) Combination of pulse methylprednisolone infusions with cyclosporine-based immunosuppression is safe and effective to treat recurrent focal segmental glomerulosclerosis after pediatric kidney transplantation. Clin Transpl 27:E143–E150. https://doi.org/10.1111/ctr.12079
Cameron JS, Blandford G (1966) The simple assessment of selectivity in heavy proteinuria. Lancet 2:242–247. https://doi.org/10.1016/s0140-6736(66)92539-6
Mallick NP, Short CD, Manos J (1983) Clinical membranous nephropathy. Nephron 34:209–219. https://doi.org/10.1159/000183018
Laurent J, Philippon C, Lagrue G, Laurent G, Weil B, Rostoker G (1993) Proteinuria selectivity index--prognostic value in lipoid nephrosis and related diseases. Nephron 65:185–189. https://doi.org/10.1159/000187472
Bazzi C, Petrini C, Rizza V, Arrigo G, D'Amico G (2000) A modern approach to selectivity of proteinuria and tubulointerstitial damage in nephrotic syndrome. Kidney Int 58:1732–1741. https://doi.org/10.1046/j.1523-1755.2000.00334.x
Hattori M, Akioka Y, Chikamoto H, Kobayashi N, Tsuchiya K, Shimizu M, Kagami S, Tsukaguchi H (2008) Increase of integrin-linked kinase activity in cultured podocytes upon stimulation with plasma from patients with recurrent FSGS. Am J Transplant 8:1550–1556. https://doi.org/10.1111/j.1600-6143.2008.02287.x
Troost JP, Trachtman H, Nachman PH, Kretzler M, Spino C, Komers R, Tuller S, Perumal K, Massengill SF, Kamil ES, Oh G, Selewski DT, Gipson P, Gipson DS (2018) An outcomes-based definition of proteinuria remission in focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 13:414–421. https://doi.org/10.2215/cjn.04780517
Ohta T, Kawaguchi H, Hattori M, Komatsu Y, Akioka Y, Nagata M, Shiraga H, Ito K, Takahashi K, Ishikawa N, Tanabe K, Yamaguchi Y, Ota K (2001) Effect of pre- and postoperative plasmapheresis on posttransplant recurrence of focal segmental glomerulosclerosis in children. Transplantation 71:628–633. https://doi.org/10.1097/00007890-200103150-00008
Hattori M, Mieno M, Shishido S, Aikawa A, Ushigome H, Ohshima S, Takahashi K, Hasegawa A, Japan Society for Transplantation and Japanese Society for Clinical Renal Transplantation (2018) Outcomes of pediatric ABO-incompatible living kidney transplantations from 2002 to 2015: an analysis of the Japanese Kidney Transplant Registry. Transplantation 102:1934–1942. https://doi.org/10.1097/tp.0000000000002259
Chikamoto H, Hattori M, Kuroda N, Kajiho Y, Matsumura H, Fujii H, Ishizuka K, Hisano M, Akioka Y, Nozu K, Kaito H, Shimizu M (2012) Pretransplantation combined therapy with plasmapheresis and rituximab in a second living-related kidney transplant pediatric recipient with a very high risk for focal segmental glomerulosclerosis recurrence. Pediatr Transplant 16:E286–E290. https://doi.org/10.1111/j.1399-3046.2011.01610.x
Hattori M, Ito K, Konomoto T, Kawaguchi H, Yoshioka T, Khono M (1999) Plasmapheresis as the sole therapy for rapidly progressive Henoch-Schönlein purpura nephritis in children. Am J Kidney Dis 33:427–433. https://doi.org/10.1016/s0272-6386(99)70178-2
Cravedi P, Kopp JB, Remuzzi G (2013) Recent progress in the pathophysiology and treatment of FSGS recurrence. Am J Transplant 13:266–274. https://doi.org/10.1111/ajt.12045
Francis A, Didsbury M, McCarthy H, Kara T (2018) Treatment of recurrent focal segmental glomerulosclerosis post-kidney transplantation in Australian and New Zealand children: a retrospective cohort study. Pediatr Transplant 22:e13185. https://doi.org/10.1111/petr.13185
Canaud G, Zuber J, Sberro R, Royale V, Anglicheau D, Snanoudj R, Gaha K, Thervet E, Lefrère F, Cavazzana-Calvo M, Noël LH, Méjean A, Legendre C, Martinez F (2009) Intensive and prolonged treatment of focal and segmental glomerulosclerosis recurrence in adult kidney transplant recipients: a pilot study. Am J Transplant 9:1081–1086. https://doi.org/10.1111/j.1600-6143.2009.02580.x
Lafayette RA (2020) Facing the vexing problem of recurrent FSGS after kidney transplantation. Clin J Am Soc Nephrol 15:171–173. https://doi.org/10.2215/cjn.14841219
Kienzl-Wagner K, Waldegger S, Schneeberger S (2019) Disease recurrence-the sword of Damocles in kidney transplantation for primary focal segmental glomerulosclerosis. Front Immunol 10:1669. https://doi.org/10.3389/fimmu.2019.01669
Zimmerman SW (1985) Plasmapheresis and dipyridamole for recurrent focal glomerular sclerosis. Nephron 40:241–245. https://doi.org/10.1159/000183469
Pescovitz MD, Book BK, Sidner RA (2006) Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 354:1961–1963. https://doi.org/10.1056/nejmc055495
Araya CE, Dharnidharka VR (2011) The factors that may predict response to rituximab therapy in recurrent focal segmental glomerulosclerosis: a systematic review. J Transp Secur 2011:374213. https://doi.org/10.1155/2011/374213
Kashgary A, Sontrop JM, Li L, Al-Jaishi AA, Habibullah ZN, Alsolaimani R, Clark WF (2016) The role of plasma exchange in treating post-transplant focal segmental glomerulosclerosis: a systematic review and meta-analysis of 77 case-reports and case-series. BMC Nephrol 17:104. https://doi.org/10.1186/s12882-016-0322-7
Gipson DS, Troost JP, Lafayette RA, Hladunewich MA, Trachtman H, Gadegbeku CA, Sedor JR, Holzman LB, Moxey-Mims MM, Perumal K, Kaskel FJ, Nelson PJ, Tuttle KR, Bagnasco SM, Hogan MC, Dell KM, Appel GB, Lieske JC, Ilori TO, Sethna CB, Fervenza FC, Hogan SL, Nachman PH, Rosenberg AZ, Greenbaum LA, Meyers KE, Hewitt SM, Choi MJ, Kopp JB, Zhdanova O, Hodgin JB, Johnstone DB, Adler SG, Avila-Casado C, Neu AM, Hingorani SR, Lemley KV, Nast CC, Brady TM, Barisoni-Thomas L, Fornoni A, Jennette JC, Cattran DC, Palmer MB, Gibson KL, Reich HN, Mokrzycki MH, Sambandam KK, Zilleruelo GE, Licht C, Sampson MG, Song P, Mariani LH, Kretzler M (2016) Complete remission in the Nephrotic Syndrome Study Network. Clin J Am Soc Nephrol 11:81–89. https://doi.org/10.2215/CJN.02560315
Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC, Toronto Glomerulonephritis Registry Group (2005) Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol 16:1061–1068. https://doi.org/10.1681/ASN.2004070593
Bökenkamp A (2020) Proteinuria – take a closer look! Pediatr Nephrol 35:533–541. https://doi.org/10.1007/s00467-019-04454-w
Hattori M, Chikamoto H, Akioka Y, Nakakura H, Ogino D, Matsunaga A, Fukazawa A, Miyakawa S, Khono M, Kawaguchi H, Ito K (2003) A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis 42:1121–1130. https://doi.org/10.1053/j.ajkd.2003.08.012
Alasfar S, Matar D, Montgomery RA, Desai N, Lonze B, Vujjini V, Estrella MM, Manllo Dieck J, Khneizer G, Sever S, Reiser J, Alachkar N (2018) Rituximab and therapeutic plasma exchange in recurrent focal segmental glomerulosclerosis postkidney transplantation. Transplantation 102:e115–e120. https://doi.org/10.1097/tp.0000000000002008
We thank Ellen Knapp, PhD, and Traci Raley, MS, ELS, from Edanz Group (https://en-author-services.edanzgroup.com/ac) for editing drafts of this manuscript.
This work was supported in part by Grants-in-Aid Scientific Research (C) (JP18K07857 to MH, JP18K07830 to KM, and JP18K07029 to KI) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
This study was approved by the ethical committee of Tokyo Women’s Medical University, School of Medicine (approval number 4968).
Conflict of interest
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Ban, H., Miura, K., Kaneko, N. et al. Amount and selectivity of proteinuria may predict the treatment response in post-transplant recurrence of focal segmental glomerulosclerosis: a single-center retrospective study. Pediatr Nephrol (2021). https://doi.org/10.1007/s00467-021-04951-x
- Focal segmental glomerulosclerosis
- Post-transplant recurrence
- Predictive factor
- Treatment response